Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinefungin is a natural nucleoside analog isolated from Streptomyces species, structurally related to S‑adenosylmethionine and S‑adenosylhomocysteine. It acts as a potent competitive inhibitor of methyltransferases that use S‑adenosylmethionine as a methyl donor, including DNA methyltransferases (DNMTs), RNA methyltransferases (such as mRNA(guanine-N7)-methyltransferase and mRNA(nucleoside‑2′)-methyltransferase), and protein lysine methyltransferases like SET7/9. Through this inhibition, it blocks the transfer of methyl groups to DNA, RNA, or proteins. Biologically, sinefungin exhibits antifungal, antimicrobial, antiviral, and antiparasitic activities; it has shown efficacy against various fungi and protozoan parasites such as Leishmania spp., Trypanosomes, Plasmodium spp., Cryptosporidium parvum (notably in animal models), and can inhibit viral replication by targeting viral mRNA capping enzymes. Its main research applications are in epigenetics (as an inhibitor of histone H3K4 monomethylation) and infectious disease models[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sinefungin.